Ingenol mebutate: an introduction.

Abstract

The incidence of nonmelanoma skin cancer continues to increase. While surgical excision remains the mainstay of treatment, growing demand from patients for effective, tissue-sparing approaches with good cosmetic results has led to the development of novel therapeutic agents. Several studies have reported on the safety and efficacy of topical ingenol mebutate gel, a derivative of the plant Euphorbia peplus, in the treatment of actinic keratosis and superficial basal cell carcinoma. An understanding of the history, mechanism of action, and recent trial evidence for this emerging therapy can assist physicians in counseling patients on available treatment options and in selecting appropriate therapy.

• Authors: Robyn S Fallen, Melinda Gooderham
• Journal: Skin therapy letter (Skin Therapy Lett) Vol. 17 Issue 2 Pg. 1-3 (Feb 2012) ISSN: 1201-5989 [Print] Canada
• PMID: 22358305 (Publication Type: Journal Article)

Chemical References

• 3-ingenyl angelate
• Antineoplastic Agents, Phytogenic
• Diterpenes

Topics

• Administration, Cutaneous
• Antineoplastic Agents, Phytogenic (adverse effects, pharmacology, therapeutic use)
• Carcinoma, Basal Cell (drug therapy, pathology)
• Diterpenes (adverse effects, pharmacology, therapeutic use)
• Euphorbia (chemistry)
• Humans
• Keratosis, Actinic (drug therapy, pathology)
• Skin Neoplasms (drug therapy, pathology, surgery)